JP2009520502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520502A5 JP2009520502A5 JP2008547425A JP2008547425A JP2009520502A5 JP 2009520502 A5 JP2009520502 A5 JP 2009520502A5 JP 2008547425 A JP2008547425 A JP 2008547425A JP 2008547425 A JP2008547425 A JP 2008547425A JP 2009520502 A5 JP2009520502 A5 JP 2009520502A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oligonucleotide
- allergen
- adjuvant
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 49
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 239000002671 adjuvant Substances 0.000 claims 20
- 239000013566 allergen Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 239000002246 antineoplastic agent Substances 0.000 claims 20
- 239000000074 antisense oligonucleotide Substances 0.000 claims 20
- 238000012230 antisense oligonucleotides Methods 0.000 claims 20
- 229940127089 cytotoxic agent Drugs 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 14
- 230000003308 immunostimulating effect Effects 0.000 claims 13
- 238000004519 manufacturing process Methods 0.000 claims 11
- 230000002519 immonomodulatory effect Effects 0.000 claims 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000037883 airway inflammation Diseases 0.000 claims 8
- 230000007815 allergy Effects 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000027866 inflammatory disease Diseases 0.000 claims 8
- 244000052769 pathogen Species 0.000 claims 8
- 208000017520 skin disease Diseases 0.000 claims 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 239000000443 aerosol Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000007933 dermal patch Substances 0.000 claims 3
- 239000003889 eye drop Substances 0.000 claims 3
- 229940012356 eye drops Drugs 0.000 claims 3
- 239000002324 mouth wash Substances 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 210000001215 vagina Anatomy 0.000 claims 3
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 claims 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 claims 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 claims 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 claims 2
- 229940029575 guanosine Drugs 0.000 claims 2
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 claims 1
- 239000002718 pyrimidine nucleoside Substances 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75233505P | 2005-12-20 | 2005-12-20 | |
| US82145806P | 2006-08-04 | 2006-08-04 | |
| PCT/US2006/048362 WO2007084237A2 (en) | 2005-12-20 | 2006-12-19 | Novel synthetic agonists of toll-like receptors containing cg dinucleotide modifications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009520502A JP2009520502A (ja) | 2009-05-28 |
| JP2009520502A5 true JP2009520502A5 (cg-RX-API-DMAC7.html) | 2010-02-18 |
Family
ID=38288084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547425A Pending JP2009520502A (ja) | 2005-12-20 | 2006-12-19 | Cgジヌクレオチド修飾物を含有するトール様受容体の新規な合成アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080279785A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1962896A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009520502A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006336242A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2632943A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008008278A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007084237A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| KR100985457B1 (ko) | 2001-06-21 | 2010-10-06 | 다이나박스 테크놀로지 코퍼레이션 | 키메라 면역조절 화합물 및 그것들의 사용 방법 |
| US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| CN101820908A (zh) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | 包含改性糖部分的免疫刺激寡核苷酸类似物 |
| JP2012516352A (ja) * | 2009-01-30 | 2012-07-19 | イデラ ファーマシューティカルズ インコーポレイテッド | Tlr9の合成アゴニスト |
| KR101856462B1 (ko) | 2009-03-25 | 2018-05-10 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물 |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| JP6121597B1 (ja) * | 2016-06-09 | 2017-04-26 | 株式会社スリービー | 免疫応答活性化サイトカイン産生促進剤およびTh17細胞分化促進剤 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| US6346614B1 (en) * | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
| TW244371B (cg-RX-API-DMAC7.html) * | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
| US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| EP2292632A3 (en) * | 2000-09-26 | 2012-07-25 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| JP4874801B2 (ja) * | 2003-06-11 | 2012-02-15 | イデラ ファーマシューティカルズ インコーポレイテッド | 安定化免疫調節オリゴヌクレオチド |
| US7276486B2 (en) * | 2004-03-15 | 2007-10-02 | Kimberly-Clark Worldwide, Inc. | Compositions for vaginal treatment |
-
2006
- 2006-12-19 JP JP2008547425A patent/JP2009520502A/ja active Pending
- 2006-12-19 CA CA002632943A patent/CA2632943A1/en not_active Abandoned
- 2006-12-19 EP EP06849308A patent/EP1962896A4/en not_active Withdrawn
- 2006-12-19 US US11/641,590 patent/US20080279785A1/en not_active Abandoned
- 2006-12-19 AU AU2006336242A patent/AU2006336242A1/en not_active Abandoned
- 2006-12-19 MX MX2008008278A patent/MX2008008278A/es active IP Right Grant
- 2006-12-19 WO PCT/US2006/048362 patent/WO2007084237A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521218A5 (ja) | 免疫調節オリゴヌクレオチド(imo(tm))の免疫賦活作用 | |
| RU2007101039A (ru) | Иммуностимулирующие олигонуклеотидные мультимеры | |
| ES2307568T3 (es) | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. | |
| ES2600553T3 (es) | Ácidos nucleicos inmunoestimuladores | |
| ES2552471T3 (es) | Conjugados de agonistas de TLR sintéticos y usos de los mismos | |
| JP6406793B2 (ja) | トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド(iro)化合物 | |
| ES2526879T3 (es) | Composiciones y procedimientos para formulaciones de oligonucleótidos | |
| ES2544958T3 (es) | Análogos de oligonucleótidos CpG que contienen análogos de T hidrófobos con actividad inmunoestimuladora potenciada | |
| ES2486298T3 (es) | Análogos de oligonucleótidos inmunoestimuladores que contienen azúcares modificados | |
| US7427405B2 (en) | Immunostimulatory oligonucleotide multimers | |
| JP2009515823A5 (cg-RX-API-DMAC7.html) | ||
| WO2006080946A3 (en) | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist | |
| JP2001503254A (ja) | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 | |
| JP2008516634A5 (cg-RX-API-DMAC7.html) | ||
| KR20160045726A (ko) | 면역조절제로서의 구형 핵산-기재 구축물 | |
| JP2007509983A (ja) | 免疫刺激力が増強されたc−クラスのオリゴヌクレオチドアナログ | |
| JP2009132737A (ja) | 刺激性免疫応答用の核酸組成物 | |
| WO2009048945A8 (en) | Rapid mucosal gel or film insulin compositions | |
| JP2008531018A5 (cg-RX-API-DMAC7.html) | ||
| JP2010532996A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0610449A2 (pt) | métodos para tratar asma exarcebada por doença infecciosa | |
| ES3035198T3 (en) | Cpg amphiphiles and uses thereof | |
| JP2012528867A5 (cg-RX-API-DMAC7.html) | ||
| ES2544484T3 (es) | Análogos de oligonucleótidos modificados con fosfato con actividad inmunoestimulante | |
| ES2834906T3 (es) | Oligonucleótidos de cadena sencilla para la utilización en el tratamiento médico de trastornos de la piel |